RISEUPTOHIV
RISEUPTOHIV
EDUCATION • COMMUNITY • RESOURCES
About Contact
ES HT
Science & Care

Aging with HIV: The Epidemic Grew Up

Last reviewed:

Health information — Educational information, not medical advice. Talk with your healthcare provider about your care and treatment decisions.
The medicine kept us alive. The healthcare system still hasn't caught up with what that means.

More than half of people with HIV in the U.S. are now 50 or older, and that share keeps climbing. Antiretroviral therapy (ART) turned what was once a fatal diagnosis into a chronic condition with near-normal life expectancy. But aging with HIV brings its own realities — earlier comorbidities, polypharmacy, cognitive changes, bone loss, frailty, and a healthcare system that wasn't built for this.

Share this article Facebook X WhatsApp Text Email LinkedIn Reddit Threads Bluesky
← Learning Hub

The Big Picture Aging with HIV, by the Numbers

The demographics of HIV in the United States have shifted dramatically. What was once seen as a disease of young adults is now increasingly a condition managed by people in their 50s, 60s, and beyond.[1] This isn't a failure — it's a testament to how well ART works. But it means the healthcare system needs to evolve alongside the population it serves.

~54% of people with diagnosed HIV in the U.S. are 50 or older (2023 CDC data)[2]
53–75% projected to be 50+ by 2040, depending on new-diagnosis trends[3]
Earlier some bone and other age-related conditions can occur earlier; timing varies[4]
~4 in 10 of people living with HIV in U.S. cohorts report polypharmacy — 5 or more medications[5]

Only 19% of people 65 and older had ever been tested for HIV as of 2022, and just 71% of people 65+ living with HIV received care in 2023 — the lowest of any age group.[6] When older adults are diagnosed, they're more likely to already have late-stage infection. Late diagnosis means more immune damage, a harder recovery, and a steeper road ahead — which is one reason many advocates argue current CDC screening guidance (routine testing ages 13–64) should be extended to older adults.[7]

This matters for everyone, not just long-term survivors. Whether you were diagnosed at 25 and are now 55, or diagnosed at 60 last year, aging with HIV needs a care approach that reaches beyond viral suppression. The virus is controlled — now the question is what the rest of your health looks like.

The Science Accelerated Aging: What the Research Shows

Even with viral suppression, HIV appears to accelerate certain aspects of the aging process. The mechanisms are complex and still being studied, but several factors are now well established.

Chronic immune activation and inflammation. Even when the virus is fully suppressed, people living with HIV carry higher levels of systemic inflammation and immune activation than their HIV-negative peers. This persistent low-grade inflammation — sometimes called "inflammaging" — drives tissue damage across multiple organ systems over time and helps explain the elevated cardiovascular, bone, and cognitive risks that follow.[8]

Epigenetic aging. Some studies find higher DNA-methylation age estimates in people with HIV. A 2015 study reported an average difference of about 5 years in blood samples and 7 years in brain tissue. These are research measures that vary by tissue and study; they do not tell an individual how old their body is or how long they will live.[9]

Immune exhaustion. Years of managing HIV — even fully suppressed HIV — takes a cumulative toll on the immune system. T-cell populations show signs of premature aging, with reduced ability to respond to new infections, cancers, and vaccines. This is called immunosenescence, and it happens earlier in people with HIV than in the general population.

The medicine kept us alive — and that is extraordinary. But we are not aging the same way as everyone else, and our care has to reflect that.

What to Watch For Comorbidities: The Conditions That Travel with HIV

People aging with HIV face a higher burden of age-related comorbidities — and tend to develop them earlier. A 2015 model based on the Netherlands ATHENA cohort projected that 84% of people receiving ART would have at least one noncommunicable condition by 2030 and 28% would have three or more. These were forecasts for that setting, not current worldwide measurements.[10] Here are the major ones to understand.

Heart and blood vessels

Heart health remains part of HIV care even when treatment is working well. NIH's May 2026 update points to a recommendation for primary-prevention statins in people living with HIV ages 40–75. The discussion should include your full risk profile, possible benefits and harms, and medication interactions, not only a cholesterol result. [22]

For people younger than 40, the HIV-specific evidence is insufficient; decisions are individualized. If you are older than 75, ask your clinician for a plan tailored to your health and priorities rather than assuming the 40–75 recommendation automatically applies. [22]

Read HIV & Heart Health for the current recommendation and what REPRIEVE found.

Metabolic Syndrome & Diabetes

Insulin resistance and type 2 diabetes develop more often in people aging with HIV. Certain ART regimens can contribute to metabolic changes, and chronic inflammation itself drives insulin resistance. Blood-glucose screening should be routine. HbA1c can underestimate glycemia during ART, so a normal HbA1c alone cannot rule out diabetes; plasma-glucose testing is preferred for screening.[30] Weight management and dietary attention matter more for people living with HIV than for the general population because of these compounding risk factors.

Kidney Disease

HIV itself can cause kidney damage, and some antiretroviral medications — particularly tenofovir disoproxil fumarate (TDF) — carry kidney-related side effects. Regular monitoring of kidney function (eGFR and urine protein) is essential, especially for people on TDF-based regimens or with other risk factors like high blood pressure and diabetes. If you're on TDF and aging, ask your provider whether tenofovir alafenamide (TAF) might be a better fit for your bones and kidneys.

Cancer

People living with HIV have a higher risk of some cancers, not all cancers. HIV treatment has greatly reduced certain cancers compared with the earlier epidemic; immune function, persistent infections, smoking, and access to care remain important. A population-level risk is not an individual's prediction. [23]

For anal cancer, NIH recommends annual symptom assessment at every age. The age-based screening pathway begins at 35 for men who have sex with men and transgender women living with HIV, and at 45 for other people living with HIV. Anal cytology should be offered where high-resolution anoscopy and treatment are available. People with a cervix need HIV-specific cervical screening, which can continue beyond 65. [24]

People with cirrhosis continue liver-cancer surveillance after hepatitis C cure; hepatitis B surveillance depends on individual criteria. A history of hepatitis C alone does not put everyone on the same scanning schedule. [25][26]

The whole-body guide's cancer section explains ANCHOR and how to ask about screening.

Brain Health Cognitive Changes & Neurocognitive Health

Cognitive health is one of the most important — and most anxiety-producing — topics in HIV and aging. A 2021 meta-analysis of 21 studies found that older people living with HIV had about 2.4 times the odds of cognitive impairment compared with HIV-negative peers.[14] Cognitive difficulties can occur despite viral suppression, but that pooled estimate is not a prediction for every treated person.

HIV-associated neurocognitive disorder (HAND) is a spectrum that ranges from asymptomatic neurocognitive impairment (detectable only on formal testing) to significant impairment that affects daily functioning. The severe HIV dementia common in the pre-ART era is now rare — dropping from about 15% to under 5% among people on suppressive ART — but milder forms of HAND remain common.[15]

Brain imaging studies show that people with HIV — even those who are virally suppressed — can have lower gray matter volume and white matter changes compared to matched controls. Effective ART can help improve cognition, and maintaining viral suppression remains the single most important thing you can do for your brain health.

What you can do: Stay virally suppressed. Exercise regularly — cardiovascular exercise is neuroprotective. Manage cardiovascular risk factors (they affect brain health too). Stay socially and mentally engaged. If you notice memory or concentration changes, bring them up with your provider — early identification matters. Neuropsychological testing can establish a baseline and track changes over time.

Musculoskeletal Bone Health & Osteoporosis

Bone density loss is more common and starts earlier in people with HIV. Multiple factors contribute: HIV-related chronic inflammation, certain ART medications (particularly TDF), lower vitamin D levels, lower body weight, smoking, and the effects of aging itself. A meta-analysis found higher odds of low bone density in people with HIV: about 2.4 at the spine and 2.6 at the hip compared with controls. Results differed by treatment group and skeletal site; these are odds estimates, not annual fracture rates.[16]

The result is higher rates of osteopenia and osteoporosis, and a meaningfully increased fracture risk — with fragility fractures occurring about 10 years earlier in people living with HIV than in the general population.[17] Hip fractures in particular carry serious consequences for older adults: long recovery times, loss of independence, and higher mortality risk.

Medications Polypharmacy: When the Pill Count Adds Up

As comorbidities accumulate, so do medications. Roughly 4 in 10 people living with HIV in U.S. cohorts report polypharmacy — commonly defined as taking 5 or more medications concurrently — and the share climbs steeply with age and with each additional comorbidity.[5] This creates a cascade of clinical concerns: drug-drug interactions, side effects that compound each other, adherence burden, and the risk of one medication undermining another.

ART medications interact with a wide range of other drugs — statins, blood pressure medications, antidepressants, acid-reflux medications, blood thinners, and more. The liver enzymes that metabolize ART are often the same ones processing these other medications, and that competition can raise or lower drug levels unpredictably. Integrase inhibitor-based regimens (dolutegravir, bictegravir) tend to have fewer such interactions than older boosted protease-inhibitor regimens.

The single most important thing you can do: Keep a complete, updated medication list — including over-the-counter drugs and supplements — and bring it to every appointment. Make sure your HIV provider knows everything you're taking, and make sure every other specialist knows you're on ART. Ask your pharmacist to run an interaction check at least annually. Integrase inhibitor-based ART regimens tend to have fewer drug interactions than older regimens.

Who is keeping the whole plan together?

Managing HIV alongside other conditions can mean several clinicians, prescriptions, tests, and bills. KFF Health News's June 2024 reporting on aging with HIV describes how fragmented care makes that work harder; needing help to coordinate it is not a personal failure. [27]

Bring one medication list, including nonprescription products and supplements. Interactions matter when combining HIV treatment with statins or hepatitis C medicines, and changing an HIV regimen can also affect hepatitis B treatment. [22][28][26]

Hepatitis A, B, and C: a separate part of the liver plan

These are different viruses, not stages of one illness. A and B have vaccines; C has no vaccine, but modern antiviral treatment can usually cure it. [29]

For people with HIV and hepatitis B, stopping medicines that also suppress hepatitis B can cause a serious flare. This matters when changing HIV regimens as well as when stopping medication altogether. Coordinate any switch with the care team. [26]

Hepatitis C cure does not erase every existing liver risk. People with cirrhosis still need liver-cancer surveillance after cure. [25]

Use the combined hepatitis guide for tests, vaccines, treatment, and follow-up, and the short printable guide to organize a visit.

Functional Health Frailty: It's Not Just About Getting Older

Frailty describes a loss of physiologic reserve — reduced strength, endurance, and resilience — that goes beyond normal aging. It predicts falls, hospitalizations, disability, and death. People with HIV develop frailty at higher rates and at younger ages than their HIV-negative peers.[18]

Frailty isn't inevitable. It can be slowed, stabilized, and in some cases reversed with the right interventions. The key is early identification — by the time frailty is obvious, intervention is harder.

Mental Wellness Depression, Isolation & Aging Alone

Depression and anxiety are important concerns for people aging with HIV. The reasons are layered: grief from the epidemic years, survivor's guilt, the cumulative weight of stigma, physical health challenges, and the particular loneliness of aging with a condition many people still don't understand.[19]

Social connection deserves attention alongside physical health. Some long-term survivors experienced repeated bereavements or lost much of their support network; others have strong networks or different histories. Privacy concerns, stigma, mobility, and access to welcoming services can also affect connection. Ask about loneliness and available support rather than assuming that living alone means someone is isolated. Read about grief and connection.

A Swiss cohort study found elevated suicide mortality among people with HIV compared with the general population, even in the later ART era. The study does not establish the same risk for every country or every virally suppressed person.[20] Depression screening should be a routine part of every HIV care visit — annually at minimum.

You are not alone in this. Depression, isolation, and grief are not signs of weakness, and they are not inevitable parts of surviving HIV. Talk with your care team about what you are experiencing and what kind of support would help. Peer connection, counseling, and practical assistance can complement one another. See our mental health guide and survivor networks in the Community hub.

Taking Action Building an Aging-with-HIV Care Plan

The goal isn't to be afraid of aging — it's to be informed and proactive. Here's what a comprehensive care approach looks like for someone aging with HIV.

Monitoring to review with your care team

This is a conversation checklist, not a requirement to order every test every year. Ask which items apply to your age, anatomy, symptoms, prior results, and medications, and get the recommended dates in writing.

Conversations to Have with Your Provider

Many of the screenings above won't happen unless you ask for them. HIV providers are excellent at managing your virus — but aging-related care often falls through the gaps, especially if you don't have a primary care provider in addition to your HIV specialist. Here are the conversations worth initiating:

"I'd like to talk about my long-term health plan." This opens the door to everything — cardiovascular risk, bone density, cancer screening, mental health, and advance care planning. Your provider should be able to order the appropriate tests or refer you to the right specialists.

Advance care planning. This is a topic that gets overlooked now that people with HIV are living longer. In the early epidemic, these conversations were routine. Now they're not — but they should be. Who makes medical decisions for you if you can't? Do you have a healthcare power of attorney and advance directive? These documents matter for everyone, but especially for people navigating complex chronic conditions.

Florida In Focus Finding Age-Informed HIV Care in Florida

Finding providers who understand both HIV and geriatric health — or who are willing to learn — makes a real difference. In Florida, Ryan White clinics are a strong entry point, and academic medical centers with HIV programs can coordinate the specialists (cardiology, endocrinology, geriatrics, psychiatry) that aging-related care often requires.[21]

RiseUpToHIV Florida Locator Find HIV specialty providers across Florida. Ask your Ryan White clinic about referrals to geriatrics, cardiology, endocrinology, and mental health providers experienced with people living with HIV. Find Care Near You →
University of Miami Health Academic medical center with HIV and aging expertise. Their HIV program connects to multiple specialty services under one system. umiamihealth.org →
Tampa General Hospital Major academic center serving central Florida with HIV, geriatric, and specialty care programs. tgh.org →
ACRIA / GMHC National leader in research and resources on HIV and aging. Their publications and programs address the unique needs of older adults with HIV. gmhc.org →

Aging with HIV is not a failure — it's one of the great success stories of modern medicine. The challenge now is making sure the care catches up with the survival. You made it this far. The system owes you care that reflects that.

RiseUpToHIV.com — Built by a person living with HIV. Independent. Community-led. Florida-focused.

References & Sources

  1. HIV.gov, "Aging with HIV" — 54% of the 1.1 million people with diagnosed HIV in the U.S. were age 50+ in 2023. ↩
  2. CDC / HIV.gov, "Aging with HIV" (2023 NHSS data, 597,296 people living with HIV aged 50+). ↩
  3. O’Connor SM et al., "Projected Increases in Older People With HIV in the United States Through 2040," HIV-SALT model, 2025 — 53% to 75% projected age-50+ share by 2040 depending on diagnosis-trajectory scenario. ↩
  4. Biver E., "Osteoporosis and HIV Infection," Calcified Tissue International 2022 — review of bone loss and fracture risk in people with HIV. ↩
  5. Danjuma MI et al., "Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis," Ther Adv Drug Saf 2022 — pooled polypharmacy prevalence 33% globally, 44% in the Americas. See also CDC Preventing Chronic Disease (42.1% U.S. sample). ↩
  6. AIDSVu, "National HIV/AIDS and Aging Awareness Day Toolkit 2025" — 19% of individuals 65+ ever tested for HIV (2022); 71% of people living with HIV 65+ received care in 2023. ↩
  7. CDC, HIV Testing Guidelines — routine screening recommended for all adolescents and adults ages 13–64. ↩
  8. Obare LM et al., "Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease," Circulation Research 2024 — chronic inflammation as driver of multi-system comorbidity in treated HIV. ↩
  9. Horvath S, Levine AJ, "HIV-1 Infection Accelerates Age According to the Epigenetic Clock," J Infect Dis 2015 — DNA-methylation age advancement of ~5 years in people living with HIV. ↩
  10. Smit M et al., "Future challenges for clinical care of an ageing population infected with HIV: a modelling study," Lancet Infect Dis 2015 — foundational Netherlands ATHENA cohort projections for HIV comorbidity burden. ↩
  11. American Heart Association, "As HIV patients live longer, heart disease might be their next challenge" — 1.5–2× increased CVD risk in people living with HIV.
  12. Grinspoon SK et al., REPRIEVE trial, and HHS Adult and Adolescent ARV Guidelines — statin therapy for primary CVD prevention in people living with HIV aged 40–75. See PubMed 37486775.
  13. National Cancer Institute, "HIV Infection and Cancer Risk" — elevated risk of lung, liver, and anal cancers in people living with HIV.
  14. Deng L et al., "Association of HIV-infection and Cognitive Impairment in Older Adults: A Meta-Analysis," 2021 — pooled OR 2.44 (95% CI 1.69–3.53) for global cognitive impairment. ↩
  15. Chan P, Valcour V, "Neurocognition and the Aging Brain in People With HIV," 2022 — HAND spectrum and prevalence in the ART era. ↩
  16. Goh SSL et al. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors. Osteoporosis International 2018;29:595–613. ↩
  17. Biver E et al., "Osteoporosis and HIV Infection," Calcified Tissue International 2022 — fragility fractures ~10 years earlier in people living with HIV. ↩
  18. Erlandson KM, Piggott DA, "Frailty and HIV: Moving from Characterization to Intervention," Current HIV/AIDS Reports 2021 — frailty prevalence, mechanisms, and reversibility. ↩
  19. HIV.gov, "Mental Health" — depression and anxiety in people living with HIV. ↩
  20. Ruffieux Y et al., "Mortality from suicide among people living with HIV," Journal of the International AIDS Society 2019 — suicide mortality in the Swiss HIV Cohort and general Swiss population. ↩
  21. HRSA Ryan White HIV/AIDS Program, ryanwhite.hrsa.gov — federal safety-net program for people with HIV, including older adults. ↩
  22. NIH: Update on statin therapy for people with HIV. Checked September 18, 2026. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/statin-therapy-people-hiv Return to article
  23. NCI: HIV infection and cancer risk. Checked September 18, 2026. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/hiv-fact-sheet Return to article
  24. NIH: Human papillomavirus disease. Checked September 18, 2026. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/human Return to article
  25. AASLD/IDSA: Monitoring during and after HCV treatment. Checked September 18, 2026. https://www.hcvguidelines.org/guidance/monitoring-patients-who-are-starting-hcv-treatment-are-on-treatment-or-have-completed-therapy/ Return to article
  26. NIH: Hepatitis B/HIV coinfection. Checked September 18, 2026. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/coinfections-hepatitis-b-virus-hiv Return to article
  27. KFF Health News: Aging with HIV and care needs. Checked September 18, 2026. https://kffhealthnews.org/aging/aging-with-hiv-medication-health-issues-federal-funding-legislation/ Return to article
  28. AASLD/IDSA: People with HIV/HCV coinfection. Checked September 18, 2026. https://www.hcvguidelines.org/guidance/patients-with-hiv-hcv-coinfection/ Return to article
  29. CDC: Clinical overview of viral hepatitis. Checked September 18, 2026. https://www.cdc.gov/hepatitis/hcp/clinical-overview/index.html Return to article
  30. HIVMA/IDSA. Primary Care Guidance for Providers Who Care for Persons With HIV: 2024 Update. Glucose screening, bone density, and vitamin D guidance. ↩
Search RiseUpToHIV